Tandem Diabetes Care, Inc. announced that its t:slim X2 insulin pump, equipped with the advanced Control-IQ+ automated insulin delivery technology, is now integrated with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. This launch marks the first phase of a global rollout aimed at expanding choice and personalization for people living with diabetes worldwide.
The integration combines Tandem’s trusted t:slim X2 pump with Abbott’s latest sensor technology, currently the smallest continuous glucose monitor available. The FreeStyle Libre 3 Plus offers an extended 15-day wear time and transmits glucose readings every minute directly to the pump. The Control-IQ+ algorithm adjusts insulin delivery every five minutes based on predicted glucose levels and features AutoBolus, which automatically calculates and delivers correction doses to reduce the impact of missed meal boluses and simplify daily diabetes management.
Tandem CEO John Sheridan said the combination unites the company’s most advanced algorithm with Abbott’s latest CGM innovation on Tandem’s proven pump platform. The new integration is immediately available in the U.S., preloaded on all new t:slim X2 pumps and accessible to existing users through a free remote software update. Eligible users will receive email instructions for activating the new feature. Tandem plans to expand access globally with early international programs later this year and full commercial availability expected throughout 2026.
Click here to read the original news story.